Danazol (Synonyms: Danocrine,Ladogal,NSC 270916,WIN 17,757) |
Catalog No.GC10785
One-Click Copy Product Info
|
Danazol is a synthetic anabolic steroid with properties of inhibition of interleukin-1 and TNF-α production.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 17230-88-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Danazol is a synthetic anabolic steroid with properties of inhibition of interleukin-1 and TNF-α production[1]. Danazol has antigonadotrophic effects, suppressing follicle-stimulating hormone and luteinizing hormone at the hypothalamic-pituitary level, and Danazol is an impeded androgen with anabolic and attenuated masculinizing properties[2]. Danazol has been widely used to alter red cell membranes directly to increase the surface area, enhancing the resistance to osmotic lysi[3].
In vitro, Danazol treatment for 48 hours significantly inhibited the viability of MDAMB-231 and MCF-7 cells, with IC50 values of 65μM and 31μM, respectively[4]. Treatment with 100μM Danazol for 24 hours reduced the proliferation of human umbilical vein endothelial cells (HUVECs) and decreased the formation of tubular structures[5]. 30μM Danazol treatment for 72 hours induced a cell cycle arrest in Mcf10A cells, decreased mitochondrial membrane potential, and promoted the downregulation of energy metabolism transcripts[6].
In vivo, Danazol, administered at an oral dose of 100mg/kg (5 times a week) significantly prolonged survival of female lupus MRL/MpJ mice and decreased serum amyloid protein (SAP) levels during the 200-day experiment[7]. Consecutively administered intraperitoneal injection of Danazol (4mg/kg/day) for 6 days, extended the survival of mice undergoing allogeneic cardiac grafts and maintained the generation of regulatory CD4+ cells in mice[8]. Subcutaneous injection of Danazol (25mg/kg), three times a week for 4 weeks, inhibited the progression of endometriosis in the female nude mouse model of endometriosis and led to the formation of fibrotic and avascular lesions[9].
References:[1] Jaime-Pérez J C, Colunga-Pedraza P R, Gómez-Ramírez C D, et al. Danazol as first-line therapy for aplastic anemia[J]. Annals of hematology, 2011, 90(5): 523-527.
[2] Letchumanan P, Thumboo J. Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review[C]//Seminars in arthritis and rheumatism. WB Saunders, 2011, 40(4): 298-306.
[3] Ahn Y S, Fernandez L F, Kim C I, et al. Danazol therapy renders red cells resistant to osmotic lysis 1[J]. The FASEB journal, 1989, 3(2): 157-162.
[4] Deka S J, Roy A, Ramakrishnan V, et al. Danazol has potential to cause PKC translocation, cell cycle dysregulation, and apoptosis in breast cancer cells[J]. Chemical biology & drug design, 2017, 89(6): 953-963.
[5] Thomas G W, Rael L T, Shimonkevitz R, et al. Effects of danazol on endothelial cell function and angiogenesis[J]. Fertility and sterility, 2007, 88(4): 1065-1070.
[6] Irgebay Z, Yeszhan B, Sen B, et al. Danazol alters mitochondria metabolism of fibrocystic breast Mcf10A cells[J]. The Breast, 2017, 35: 55-62.
[7] Connolly K M, Stecher V J, Snyder B W, et al. The effect of danazol in the MRL/lpr mouse model of autoimmune disease[J]. Agents and Actions, 1988, 25(1): 164-170.
[8] Uchiyama M, Jin X, Zhang Q, et al. Danazol induces prolonged survival of fully allogeneic cardiac grafts and maintains the generation of regulatory CD4+ cells in mice[J]. Transplant International, 2012, 25(3): 357-365.
[9] Ngô C, Chéreau C, Nicco C, et al. Reactive oxygen species controls endometriosis progression[J]. The American journal of pathology, 2009, 175(1): 225-234.
| Cell experiment [1]: | |
|
Cell lines |
Human umbilical vein endothelial cells (HUVECs) |
|
Preparation Method |
Human umbilical vein endothelial cells (HUVECs) were cultivated in endothelial cell medium-2 (EGM-2) supplemented with 5% fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin at 37°C in an incubator with 5% CO2. HUVECs were thawed and plated in 96-well tissue culture plates at 5000 cells/cm2 for 24h. The cells were treated with complete EGM-2 medium containing final concentrations of Danazol (0.1, 1, 10, and 100μM) in triplicates for 48h. Cell proliferation was measured. |
|
Reaction Conditions |
0.1, 1, 10, and 100μM; 48h |
|
Applications |
Danazol treatment reduced the cell viability of HUVECs in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Female nude mice |
|
Preparation Method |
Female nude mice (8 weeks of age) were housed in a specific pathogen-free (SPF) barrier environment and were continuously provided with sterilized food, water, and bedding. Mice were anesthetized with intraperitoneal injections of 500μl of 0.04M 2,2-tribromoethanol and 2.5% methyl-2-butanol. An incision was made on the ventral midline and one 5-mm2 fragment of human endometrioma was sutured to the parietal peritoneum with 7/0 Proline. The cuti was sutured with a 6/0 nylon thread. On day 14 after implantation, mice were operated to confirm the viability of the implant. Treatments started on day 14: the first group received subcutaneous injections of RU-486 (50mg/kg in 200μl of sesame oil; three times a week); the second group received subcutaneous injections of danazol (25mg/kg in 200μl of sesame oil; three times a week). The control group received intraperitoneal injections of 300μl of PBS or subcutaneous injections of 200μl of sesame oil three times a week. After 4 weeks of treatment, mice were sacrificed by cervical dislocation. Implants were extracted for histological analysis. |
|
Dosage form |
25mg/kg; three times a week; 4 weeks; s.c. |
|
Applications |
Danazol treatment caused fibrotic and avascular lesions in mice with endometriosis. |
| References: [1] Thomas G W, Rael L T, Shimonkevitz R, et al. Effects of danazol on endothelial cell function and angiogenesis[J]. Fertility and sterility, 2007, 88(4): 1065-1070. [2] Ngô C, Chéreau C, Nicco C, et al. Reactive oxygen species controls endometriosis progression[J]. The American journal of pathology, 2009, 175(1): 225-234. | |
| Cas No. | 17230-88-5 | SDF | |
| Synonyms | Danocrine,Ladogal,NSC 270916,WIN 17,757 | ||
| Chemical Name | pregna-2,4-dien-20-yno[2,3-d]isoxazol-17α-ol | ||
| Canonical SMILES | O[C@@]1(C#C)CC[C@@]2([H])[C@]3([H])CCC4=CC5=C(C=NO5)C[C@]4(C)[C@@]3([H])CC[C@@]21C | ||
| Formula | C22H27NO2 | M.Wt | 337.5 |
| Solubility | ≥ 11.05 mg/mL in DMSO, ≥ 14.84 mg/mL in EtOH with ultrasonic | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.963 mL | 14.8148 mL | 29.6296 mL |
| 5 mM | 592.6 μL | 2.963 mL | 5.9259 mL |
| 10 mM | 296.3 μL | 1.4815 mL | 2.963 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)